Key Points
- Insider sale: Director Joseph Lyssikatos sold 12,500 shares on Nov. 19 at an average of $22.33 for ~$279,125, reducing his stake by 1.37% to 902,688 shares (valued ~ $20.16M).
- Stock snapshot: ELVN traded around $21.75 midday, with a 50-day/200-day moving average of $20.44/$20.15, a market cap of $1.29B, negative P/E (-11.82), and a 1‑year range of $13.30–$26.09.
- Analyst and ownership context: The consensus rating is "Moderate Buy" with a $41.20 target (five Buys, one Sell), and institutional/hedge funds own about 95.08% of the stock.
Enliven Therapeutics, Inc. (NASDAQ:ELVN - Get Free Report) insider Joseph Lyssikatos sold 12,500 shares of the company's stock in a transaction on Wednesday, November 19th. The stock was sold at an average price of $22.33, for a total value of $279,125.00. Following the transaction, the insider owned 902,688 shares of the company's stock, valued at approximately $20,157,023.04. The trade was a 1.37% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.
Enliven Therapeutics Stock Performance
Shares of ELVN traded up $0.48 during midday trading on Friday, hitting $21.75. 348,749 shares of the stock traded hands, compared to its average volume of 618,935. The business's 50 day moving average price is $20.44 and its two-hundred day moving average price is $20.15. The firm has a market capitalization of $1.29 billion, a PE ratio of -11.82 and a beta of 0.80. Enliven Therapeutics, Inc. has a 1-year low of $13.30 and a 1-year high of $26.09.
Enliven Therapeutics (NASDAQ:ELVN - Get Free Report) last released its quarterly earnings data on Wednesday, November 12th. The company reported ($0.32) earnings per share for the quarter, topping analysts' consensus estimates of ($0.43) by $0.11. As a group, equities research analysts forecast that Enliven Therapeutics, Inc. will post -1.95 EPS for the current fiscal year.
Hedge Funds Weigh In On Enliven Therapeutics
Several hedge funds have recently modified their holdings of ELVN. Goldman Sachs Group Inc. raised its holdings in shares of Enliven Therapeutics by 61.3% in the 1st quarter. Goldman Sachs Group Inc. now owns 211,752 shares of the company's stock worth $4,167,000 after purchasing an additional 80,506 shares in the last quarter. Wellington Management Group LLP boosted its holdings in Enliven Therapeutics by 4.7% during the first quarter. Wellington Management Group LLP now owns 84,700 shares of the company's stock worth $1,667,000 after buying an additional 3,784 shares in the last quarter. Russell Investments Group Ltd. grew its position in Enliven Therapeutics by 148,550.7% in the first quarter. Russell Investments Group Ltd. now owns 105,542 shares of the company's stock worth $2,077,000 after buying an additional 105,471 shares during the last quarter. Ally Bridge Group NY LLC increased its holdings in shares of Enliven Therapeutics by 19.8% in the first quarter. Ally Bridge Group NY LLC now owns 169,774 shares of the company's stock valued at $3,341,000 after buying an additional 28,064 shares in the last quarter. Finally, Nuveen LLC bought a new position in shares of Enliven Therapeutics in the first quarter valued at $2,049,000. 95.08% of the stock is currently owned by institutional investors and hedge funds.
Analyst Ratings Changes
Several equities analysts have recently issued reports on the company. Weiss Ratings reiterated a "sell (d-)" rating on shares of Enliven Therapeutics in a research report on Wednesday, October 8th. Wall Street Zen upgraded Enliven Therapeutics from a "sell" rating to a "hold" rating in a research report on Saturday, November 15th. Five equities research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to MarketBeat.com, Enliven Therapeutics currently has a consensus rating of "Moderate Buy" and a consensus target price of $41.20.
Check Out Our Latest Report on Enliven Therapeutics
About Enliven Therapeutics
(
Get Free Report)
Enliven Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. The company's lead product candidates comprise ELVN-001, which is being evaluated in a Phase 1 clinical trial in adults with chronic myeloid leukemia; and ELVN-002, a Phase 1 clinical trial in adults with solid tumors with HER2 alterations.
Further Reading
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
